Nothing Special   »   [go: up one dir, main page]

Mirsattari et al., 2001 - Google Patents

Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica

Mirsattari et al., 2001

Document ID
14294390974937998755
Author
Mirsattari S
Johnston J
McKenna R
Del Bigio M
Orr P
Ross R
Power C
Publication year
Publication venue
Neurology

External Links

Snippet

Background: MS is common in people of northern European ethnicity who live in northern geographic areas; however, MS is rarely identified among aboriginal peoples living in the same areas. Objectives: To determine the prevalence, clinical features, HLA type, and viral …
Continue reading at www.neurology.org (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Similar Documents

Publication Publication Date Title
Mirsattari et al. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica
Wang et al. Characterization of an asymptomatic cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals outside of Wuhan, China
Weinberg et al. Quantitative CSF PCR in Epstein–Barr virus infections of the central nervous system
Orland et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study
Thakur et al. The global neurological burden of tuberculosis
Cabre et al. MS and neuromyelitis optica in Martinique (French West Indies)
Glaser et al. In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998—2000
Murphy et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors
Abel et al. Age-dependent Mendelian predisposition to herpes simplex virus type 1 encephalitis in childhood
Yamano et al. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis
Chang et al. Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits
Pifferi et al. Associations between nasal torquetenovirus load and spirometric indices in children with asthma
Rafatpanah et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran
Schulte et al. Acyclovir resistance in herpes simplex encephalitis
Fiscus et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina
Miskin et al. Diagnostic delay in progressive multifocal leukoencephalopathy
Bucciol et al. Human inherited complete STAT2 deficiency underlies inflammatory viral diseases
Lecomte et al. A clinician’s perspective on yellow fever vaccine-associated neurotropic disease
Saji et al. Progressive multifocal leukoencephalopathy
Urnovitz et al. RNAs in the sera of Persian Gulf War veterans have segments homologous to chromosome 22q11. 2
Umehara et al. Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I–associated myelopathy
Ibrahim et al. Prevalence of herpes simplex virus (types 1 and 2), varicella-zoster virus, cytomegalovirus, and human herpesvirus 6 and 7 DNA in cerebrospinal fluid of Middle Eastern patients with encephalitis
Dowran et al. Reinfection and reactivation of SARS-CoV-2
Dooneief et al. Neurologic consequences of HTLV-II infection in injection-drug users
Chavan et al. Diversity in KIR gene repertoire in HIV‐1 exposed infected and uninfected infants: A study from India